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Objective: The objective of this study was to formulate and evaluate the poorly soluble drug, naringenin (NAR) into nanosuspension to increase the 
solubility and enhance the dissolution rate and then improve its bioavailability. 
Methods: Nanosuspenion of naringenin (NARNS) was prepared using high-pressure homogenization method using Soya lecithin, Polaxamer-407, 
Polaxamer-188, Hydroxypropyl methyl cellulose (HPMC) and Tween-80. Ten formulations were prepared to show the effect of stabilizer and its 
ratio. D-α-Tocopheryl polyethene glycol succinate 1000 (TPGS) was added as a co-stabilizer. All these formulations were evaluated for their particle 
size, PDI, zeta potential, FT-IR study, drug content, saturation solubility studies, entrapment efficiency, in vitro permeability and in vitro drug 
release. The formulation was further evaluated for scanning electron microscope (SEM), differential scanning calorimetry (DSC) and Powder X-ray 
diffraction (P-XRD) and hemocompatibility assessment.  
Results: All the prepared formulations were in the nano size. The optimum concentration of the stabilizer was in the formulation was found 1:1.5:1 
(drug: stabilizer: co-stabilizer ratio). Dramatic effect of the particle size reduction was found by the addition of the co-stabilizer (TPGS) in 
formulation N2 that has P. S 80.52±0.13 nm. The solubility and dissolution of NAR in the form of NARNS were significantly higher than those of pure 
NAR. SEM report shows that naringenin nanosuspension revealed a smooth texture. P-XRD crystallography diffraction and DSC studies indicated 
that the crystalline state of NAR was converted into amorphous nature. The safety evaluation showed that NARNS provided a lower rate of 
erythrocyte hemolysis.
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Conclusion: In this study, (NARNS) was successfully carried out by high-pressure homogenization technique and characterized. The physio-
chemical characterization shown that crystalline naringenin was converted to a polymorphic form (DSC and P-XRD Study) which evidenced by 
enhanced dissolution rate in comparisons of the formulation with (NAR) pure drug. The NARNS has shown 7.5±0.4 fold increased relative 
bioavailability when compared to the NAR. The increased drug dissolution rate may have a significant impact in absorption which in turn the 
improved oral bioavailability of naringenin. Thus, this delivery system may prefer to improve the dissolution of poorly soluble drugs like NAR and 
thus enhanced oral bioavailability. The safety evaluation showed that nanoformulation (NF2) shows a lower rate of erythrocyte hemolysis. These 
findings suggest that the selected formulation may represent a promising new drug formulation for intravenous administration in the treatment of 
certain cancers. 




Cancer is a group of diseases that cause cells throughout the body to 
change and grow out of control. Most types of cancer cells eventually 
form a lump or mass called a tumor, and are named after the part 
from the body where the tumor originates. Cancer is one of the 
leading causes of death worldwide, which has been attributed to 
many factors that have influenced the increase on the number of 
cases. Some of the direct factors include the growth as the 
population, aging, and adoption of lifestyle behaviors that are known 
to cause cancer [1]. According to world health organization, more 
than 57 million deaths have occurred in 2008. Of which, 36 million 
(63 %) deaths were due to non-communicable diseases such as 
cardiovascular diseases, diabetes and cancer [2]. Of all non-
communicable diseases, with more than 7.6 million deaths, cancer 
ranked third as the leading cause of death worldwide. The current 
statistics suggest that the cancer prevalence will continue to rise and 
may reach around 17 million cancer deaths by 2030 [3, 4]. The 
major therapeutic approaches to the treatment of both localized and 
metastasized cancer in chemotherapy, which are being used alone or 
in a combination of other forms of cancer therapies [5]. However, 
the use of chemotherapeutic drugs is limited by high toxicity, rapid 
elimination from the systemic circulation, accumulation in non-
targeted organs and tissues, enzymatic and hydrolytic degradation 
and/or inefficient cell entry. Thus, the inhibition of tumor cell 
growth without side effects is recognized as an important target for 
cancer therapy. Dietary flavonoids are a widely distributed group of 
diphenolic compounds of plant origin. Epidemiological studies have 
consistently shown an inverse association between consumption of 
some nutritional flavonoids and the risk of human cancers at many 
sites [6-9]. NAR has been widely studied and has been reported to be 
an antioxidant [10, 11]
 
Fig. 1: Chemical structure NAR 
 
, NAR, and the aglycone of naringin was found 
to exhibit aorta anti-ulcer effects [12], antioxidant [13] and dilatory 
as well as inhibiting the proliferation of breast cancer and delaying 
mammary tumorgenesis. Fig. (1) Shows the chemical structure of 
naringenin [14].  
 
Regretfully, the clinical relevance of NAR is limited by its low 
solubility and minimal bioavailability owing to its largely 
hydrophobic ring structure. In addition, NAR had unfavourable body 
distribution and inability to cross-cellular barriers. Therefore 
NARNS was developed to overcome major obstacles associated with 
NAR bioavailability. One of the ways to improve the selectivity and 
effectiveness of nanoparticle delivery system is by conjugating 
nanoparticles to molecules that could specifically reach target 
cancer cells [15]. Nanotechnology is the control as a matter at 
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dimensions of roughly 1 to 100 nm, providing unique properties of 
the matter because of its small size. Nanotechnology offers many 
benefits in medicine such as protecting drugs from degradation, 
enhancing solubility of water-insoluble or poorly soluble drugs as 
well as increasing efficiency of an active ingredient. These benefits 
help to reduce drug doses which in turn decrease the risk of its side 
effect and toxicity [16]. The aim of present study was to formulate 
the NARNS in order to improve its solubility and enhance in vitro 
dissolution rate. 
MATERIALS AND METHODS 
Materials  
NAR was purchased from Zim laboratories Limited, Nagpur. Soya 
lecithin was purchased from Glenmark generics limited Mumbai, 
India. Polaxamer-188 and Polaxamr-407 were provided by Dr. 
Reddy’s Generics. TPGS was obtained from Ludwigshafen, Germany. 
Tween-80 was obtained from Nice chemicals limited, Cochin. All 
other chemicals and the solvents were of analytical reagent grade, 
and deionized water was used for this study. The experimental 
protocol was approved by the Institutional animal ethics committee 
(IAEC) of CPCSEA (Committee for the Purpose of Control and 
Supervision of Experiments on Animals), (NCP/IAEC/2015-16-04). 
Methods 
Determination of λ 
10 mg of NAR were dispersed in 100 ml 0.1N HCl pH 1.2 to prepare 0.1 
mg/ml stock solution. From this stock solution, a dilute (10 μg/ml) 
solution was prepared and scanned by UV spectrophotometer at the 
range of 200-400 nm, the same steps were repeated with phosphate 
buffer pH 7.4 to obtain the λ max of NAR in these medium [17]. 
max  
Preparation of calibration curves 
Calibration curves of NAR in 0.1 N HCl pH 1.2 and phosphate buffer 
pH 7.4 were constructed by preparing serial dilutions of the drug 
from 0.1 mg/ml stock solution for each medium. The prepared 
samples were analyzed spectrophotometrically at λ max
Fourier transform Infra-red spectroscopy 
 in these 
media. The plot of absorbance vs. concentration is done and beer's 
range was determined [18]. The results were analyzed in triplicate, 
and the standard deviation was represented. 
FT-IR spectra were recorded in the sample prepared in KBr disks (2 
mg sample in 200 mg KBr disks) using Shimadzu Fourier Transform 
Infra-Red spectrometer. The samples were scanned over a frequency 
range 4000-400 cm-1 
Formulation of naingnin nanosuspension  
[19]. 
NARNS was prepared by high pressure homogenization technique 
by using the different concentration of the stabilizers like Soya 
lecithin (N1 and N2) poloxamer 407 (N3 and N4), poloxamer 188 
(N5 and N6), Hydroxypropyl methyl cellulose (HPMC) (N7 and N8) 
and Tween-80 (N9 and N10) with (0.75 % and 1.5 %) and TPGS 
(1%) respectively, but in all the drug concentration remains 
constant. NAR powder (1 % w/v) was dispersed in aqueous 
surfactant solution using magnetic stirrer. After drug dispersion in 
the surfactant solution first size reduction step was carried out using 
an Ultra-Turax T25 basic homogenizer at 9500 rpm for 10 min. The 
obtained mixtures were homogenized using Micron-LAB 40 high-
pressure homogenizer, the homogenization step includes first two 
cycles at 100 bar and next two cycles at 500 bars pressure as an 
initial step. Finally, the suspension was homogenized for 15 cycles at 
1500 bar pressure [20]. 
 
Table 1: Composition of NARNS 
Code Drug: Polymer: TPGS ratio 
N1 1:0.75:1 (Nar: Soya lecithin: TPGS) 
N2 1:1.5:1 (Nar: Soya lecithin: TPGS) 
N3 1:0.75:1 (Nar: Polaxamer407: TPGS) 
N4 1:1.5:1 (Nar: Polaxamer407: TPGS) 
N5 1:0.75:1 (Nar: Poloxamer188: TPGS) 
N6 1:1.5:1 (Nar: Poloxamer188: TPGS) 
N7 1:0.75:1 (Nar: HPMC: TPGS) 
N8 1:1.5:1 (Nar: HPMC: TPGS) 
N9 1:0.75:1 (Nar: Tween-80: TPGS) 
N10 1:1.5:1 (Nar: Tween-80: TPGS) 
 
The homogenized nanosuspensions were freeze-dried to increase 
the shelf life of suspension and to study the dissolution behaviour. 
1% mannitol was added to each formulation as a cryoprotectant at 
the time of lyophilization. Virtis freeze drier is used for 
lyophilization of nanosuspension. At first, the sample was kept 
overnight in deep freezer at-70 °C and then the sample was kept in 
Virtis freeze drier for two d at-50 °C at 2 millitorr [21]. 
Particle size distribution and polydispersity index 
The particle size analysis of different batches of nanosuspension was 
carried out using Microtac Blue wave-particle size analyzer. Before 
measurement of the samples, they have to be diluted with de-ionized 
water to obtain a suitable concentration for measurement. The 
results obtained for particle size distributions were used to confirm 
the formation of nano-sized particles [22]. 
Zeta potential analysis 
The particle charge was one of the most important parameters in 
assessing the physical stability of emulsion and suspensions. The 
large numbers of particles were equally charged; then electrostatic 
repulsion between the particles was increased, and thereby physical 
stability of the formulation was also increased. Typically, the particle 
charge of the colloidal system was measured as zeta potential via the 
electrophoretic mobility of the particles in an electrical field. Zeta 
potential analysis of prepared nanosuspension formulation was 
carried out using Malvern Zetasizer (Malvern Instruments). Before 
measurement, the samples were diluted with de-ionized water, and 
conductivity was adjusted by addition of sodium chloride [22]. 
Re-dispersibility and percentage drug content determination 
The NARNS were analyzed for drug content by UV spectroscopic 
method. Different batches of nanosuspension equivalent to 10 mg of 
NAR weighed accurately and dissolved in 10 ml methanol. The stock 
solutions were diluted with distilled water and analyzed by UV 
spectroscopy at 290 nm [23]. 
Determination of entrapment efficiency (EE) of nanosuspension  
10 ml of nanosuspension was centrifuged at 5000 rpm for 20 min. 
The supernatant solution was filtered and separated. One ml of 
these filtrates was diluted with water and the absorbance at 
maximum λ max
The saturation solubility studies were carried out for both the 
unprocessed pure drug and different batches of lyophilized 
nanosuspension. 10 mg of unprocessed pure drug and 
nanosuspension equivalent to 10 mg of NAR was weighed and 
separately introduced into 25 ml stopper conical flask containing 10 
 was measured by UV spectrophotometer using 
water as blank [24]. The amount of free drugs in the formulations 
was measured and the entrapment efficiency is then calculated. 
Saturation solubility studies 
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ml distilled water. The flasks were sealed and placed in rotary shaker 
for 24 h at 37 °C and equivalent for 2 d. The samples were collected 
after the specified time interval, and it is filtered and analyzed. The 
samples were analyzed using UV spectrophotometer at 290 nm [25]. 
In vitro drug release studies 
The in vitro release of NAR drug and its NARNS were carried out in 
USP dissolution test apparatus using paddle method at a rotation 
speed of 50 rpm. The dissolution profile was carried out in the freshly 
prepared acidic buffer (pH 1.2) and also in the phosphate buffer (pH 
7.4). 10 mg of pure drug and nanosuspension containing 10 mg of 
naringenin equivalent was taken and placed in the dissolution 
mediums. The volume and temperature of dissolution medium were 
900 ml and 37.0±0.2 °C, respectively. Samples were withdrawn at 
fixed time intervals and were filtered. The filtered samples were 
analyzed at 290 nm using Shimadzu UV-Visible spectrophotometer. 
The results obtained for different batches of the formulation were 
compared to the dissolution profile of NAR [25, 26]. 
In vitro permeation studies 
Permeation study was carried out for both unprocessed drug and 
different batches of nanosuspension using cellulose nitrate membrane. 
The membrane was attached to the diffusion cell, and then it was dipped 
in a beaker containing phosphate buffer pH 7.4. The pure drug sample 
and equivalent quantities of lyophilized nanosuspension were weighed 
and placed in the different diffusion cell containing the specific quantity 
of buffer. The samples were withdrawn at specific time intervals for 1 hr 
and replaced with fresh buffer solution. Finally, the samples were 
analyzed using UV spectrophotometer at 290 nm [27]. 
Differential scanning calorimetry 
Thermal properties of formulations were analyzed by differential 
scanning calorimetric analysis using Toledo-DSC II. To characterize 
the changes in internal structure DSC analysis was carried out for 
NAR, polymer and the lyophilized NARNS. The 5 mg of sample was 
taken in the aluminum vial and kept in the instrument. The sample 
was then heated from 20 °C to 200 °C at a heating rate of 10 °C/min 
under a stream of nitrogen at a flow rate of 50 ml/min. Enthalpy 
changes (ΔH) were calculated peak to study the polymeric changes 
in the formulations [28]. 
Scanning electron microscopy 
The scanning electron microscopy (SEM) is one of the most 
important instruments used for analysis of surface morphology. The 
particle size analysis of lyophilized NARNS was carried out to 
confirm the nanosized of the formulation. The samples are lightly 
sprinkled on a double side adhesive tape stuck to an aluminium stub, 
and the subs were coated with platinum. The stub containing sample 
is placed in SEM chamber and analyses the surface morphology [29]. 
Powder X-ray diffraction pattern 
The P-XRD studies of nanosuspension were carried out using X-ray 
diffractometer with copper (Cu) as target filter having a 
voltage/current of 40KV/40 Ma at a scan speed of 1 °/min. The 
samples were analyzed at a 2θ angle range of 5-70 ° [30, 31]. 
Stability study 
Stability studies were carried out for naringenin nanosuspension 
formulation as per ICH guidelines. The best NARNS (N2) was sealed 
in high-density polyethene bottles and stored at 4±1 °C/Ambient, 
25±2 °C/60±5 % RH %, 40±2 °C/75±5 % RH for 90 d. The samples 
were evaluated for percentage naringenin nanosuspension. [32].  
Hemocompatibility assessment  
Whole blood cell lysis 
Blood was collected in heparinized tubes from Wistar rats and 
centrifuged for 10 min at 800×g at 4 °C. The cell pellet was 
resuspended in 0.9% NaCl solution in order to prepare a 2 % (v/v) 
cell suspension. One hundred µl of this suspension were plated in 
each well of a 96-well round bottom plate. The formulated 
nanosuspension (NF2) solutions of different concentrations (3.90–
500 µg/ml) in 0.9% (w/v) in NaCl were added to the plate and 
incubated for 1 h and 24 h at 37 °C in 5 % CO2
RESULTS AND DISCUSSION 
. The release of 
haemoglobin, as an index of red blood cell (RBC) lysis (haemolysis), 
was determined by spectrophotometric analysis of the supernatant 
at 570 nm. Complete haemolysis (positive control) was achieved by 
adding 1% (v/v) Triton X-100, while cells in 0.9 % (w/v) NaCl 
solution served as negative control [33, 34]. 
Statistical analysis 
The results were expressed as mean±SD and were analyzed 
statistically by one-way analysis of variance (ANOVA) using Graph 
Pad Prism V5.04 software at the level of significance (p<0.05). 
Determination of λ Max  
The analysis of UV spectra of naringenin in, HCl buffer pH 1.2 and 
Phosphate buffer pH 7.4 shows the same λmax
 
Fig. 1A: UV Spectrum of naringenin in-phosphate buffer pH 7.4 
 
 290 nm which similar 
to the published one as shown in fig. 1. A and 1. B [34]. 
 
 
Fig. 1B: UV Spectrum of naringenin in 0.1N HCl pH 1.2 
 
 
Fig. 2A: Standard curve of naringenin in 0.1N HCl, Regression 
Coefficient (r) = 0.999, Slope (b) = 0.00155 
Sumathi et al. 




Fig. 2B: Standard curve of naringenin in phosphate buffer, 
regression coefficient (r) = 0.999, Slope (b) = 0.00303 
 
Calibration curves of naringenin  
The constructed calibration curves of NAR in HCl buffer pH 1.2 and 
Phosphate buffer pH 7.4 are shown in fig. 2. A and 2. B. A straight line 
was obtained by plotting the absorbance versus concentration with a 
high coefficient of determination. This indicates that the calibration 
curve obeys Beer’s law within the range of concentration used. 
Formulation of nanosuspension 
NARNS were prepared by high pressure homogenization using different 
polymers such as soya lecithin (N1 and N2), Poloxamer 407 (N3 and N4), 
Poloxamer 188 (N5 and N6), HPMC (N7 and N8) and Tween-80 (N9 and 
N10) with TPGS respectively. The polymers were selected based on 
literature review and preformulation studies. The prepared 
nanosuspension was lyophilized in order to increases the stability [39].  
Particle size analysis and polydispersity index measurement 
The effect of particle size and polydispersity index (PDI) was 
studied using ten different formulations. All the prepared 
formulations were in the nano size. The mean particle size 
(effective diameter) for formulations varied in the narrow range 
from 70.89±0.0 nm to 144.5±0.0 nm. The particle size and PDI for 
different formulations are showing in table 2. The choice of 
suitable stabilizers and its concentration are the most important 
factors to control the size and stability of our work; Soya lecithin, 
Polaxamer-407, Polaxamr-188, HPMC, and Tween-80 were used at 
a different concentration (table 1). The optimum concentration 
was in the formulation of N1, N2 and N3, which has particle size 
74.37±0.16, 80.52±0.13 and 70.89±0.21 nm. Also, these 
formulation shows PDI in the range of 0.327±.0.05, 284±0.01 and 
0.293±0.09 and this low value will indicate good stability of the 
nanosuspension. The results showed that PDI is reduced with the 
increasing of stabilizer concentration as the PDI of formula N1 
which contains 1:0.75:1 of drug: (NAR: Soya lecithin: TPGS) ratio 
was 0.327±0.05 nm compared with 0.284±0.01 nm for N2 which 
contains 1:1.5:1 ratio of drug: stabilizer: Co-stabilizer. The reason 
behind this is that high stabilizer concentration decreases surface 
tension and stabilizes newly developed surfaces during high-
pressure homogenization process and produce nanosuspension of 
less PDI [35]. Furthermore, low or insufficient concentration of 
stabilizer will cause instability and recrystallization. TPGS has 
been shown to improve the bioavailability of many compounds 
[36]. The combination of TPGS and HPMC in the nanosuspension 
formulation was shown to inhibit the crystal growth within the 
system [37]. This could be attributed to the increase in the molar 
substitution ratio (MSR) of the polymer per drug. The increase of 
the hydrophilic corona surrounding the polymer to protect the 
nanosuspension enhances the stability and prevents particles from 
aggregation. The PDI values were ranged from 0.284±0.05-
0.595±0.16, which indicate the acceptable uniformity level for all 
the prepared formulations [38]. Narrower range of particles sizes 
will minimize the difference between active agent concentration 
and the surrounding environment. As a result, the Ostwald 
ripening phenomenon will be inhibited in nanosuspension during 
high-pressure homogenization methods [39, 40]. 
 
     
Fig. 3A: (N1) Fig. 3B: (N2) Fig. 3C: (N3) Fig. 3D: (N4) Fig. 3E: (N5) 
     
Fig. 3F: (N6) Fig. 3G: (N7) Fig. 3H: (N8) Fig. 3I: (N9) Fig. 3J: (N10) 
Fig. 3: Particle size distribution and PDI of nanosuspension formulation 
 
Zeta potential 
Zeta potential gives certain information on the surface charge 
properties and furthers the long-term physical stability of the 
nanosuspension. The zeta potential for the ten formulations of 
NARNS was shown in fig. 4. The charge was negative due to 
adsorbed stabillizer and TPGS on the drug particles; so, negative 
zeta potential is attributed to drug nanosuspension. In general, zeta 
potential values of±20 mV are sufficient for the stability of 
nanosuspension stabilized by the stearic stabilizer. The selected 
polymers indicating that the prepared formulation would not suffer 
from instability problems. However, the high zeta potential proposes 
that the nanosuspension was adequately stabilized. It reflects the 
electric potential of particles and is influenced by the composition of 
the particle and the medium in which it is dispersed. The obtained 
value for selected formulation indicates stable nanosuspension [41]. 
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Fig. 4A: (N1) Fig. 4B: (N2) Fig. 4C: (N3) Fig. 4D: (N4) Fig. 4E: (N5) 
     
Fig. 4F: (N6) Fig. 4G: (N7) Fig. 4H: (N8) Fig. 4I: (N9) Fig. 4J: (N10) 
Fig. 4: Zeta potential of NARNS 
 
Table 2: Particle size, polydispersity index, zeta potential, drug content and drug entrapment efficiency of naringenin nanosuspension 
S. 
No. 
Formulations Average particle size (d. 
nm) 
Poly dispersity index 
(PDI) 




Drug entrapment efficiency 
(%) 
1. N1 74.37±0.16 0.327±0.05 1.86 95.49±.63 89.0±0.23 
2. N2 80.52±0.13 0.284±0.01 -26.9 98.61±0.32 94.75±0.62 
3. N3 70.89±0.21 0.293±0.09 -13.1 94.73±0.12 88.26±0.86 
4 N4 95.94±0.16 0.359±0.69 -22.5 95.00±0.61 90.12±0.48 
5 N5 100.6±0.28 0.265±0.21 -9.56 91.34±0.56 80.45±0.01 
6 N6 106.3±0.21 0.595±0.16 -16.6 93.48±0.10 84.0±0.48 
7 N7 129.0±0.13 0.422±0.26 -1.67 89.45±0.28 78.56±0.72 
8 N8 110.7±0.64 0.318±0.21 -4.75 90.12±0.92 80.43±0.73 
9 N9 133.8±0.15 0.424±0.16 -18.6 87.34±0.26 73.69±0.73 
10 N10 144.5±0.13 0.393±0.13 -17.4 89.45±0.71 74.37±0.76 
 Mean of three observation±SD. (n=3)  
 
  
Fig. 5: FTIR spectrum of NAR Fig. 6: FTIR spectrum of soya lecithin 
  
Fig. 7: FTIR spectrum of TPGS Fig. 8: FTIR spectrum of selected formulation (N2) 
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Fourier transforms infrared spectroscopy (FT-IR) 
FT-IR spectroscopy is one of the best techniques to evaluate the 
chemical stability of the encapsulated drug inside the 
nanosuspension. Fig. 5, 6, 7, 8 shows the FT-IR spectra of free NAR, 
soya lecithin, TPGS and NARNS. FT-IR spectra confirmed the 
successful conjugation between NAR and soya lecithin with TPGS at 
∼2918.40 (CH2 symmeteric stretching) and ∼1707.27 cm -1 (C=O 
carbonyl stretching) in NAR-loaded soya lecithin nanosuspension. 
Free NAR showed the characteristic bands due to the presence of 
different functional groups. A band appearing at ∼2918.40 cm -1 is 
due to CH2 asymmetric stretching vibrations while the peak 
observed at ∼1629.60 cm -1
The Percentage drug entrapment efficiency of all the formulations 
was calculated, and the results were tabulated in table 2. The drug 
entrapment efficiency of N2 and N4 was high when compared to 
other formulations. This may be due to the presence of optimum 
polymer and TPGS concentrations, comparing the formulations N1, 
N3, N5, N6, N7, N8, N9, and N10. It is clear that increase in polymer 
concentration increased the drug entrapment efficiency. Table 2 
shows the drug entrapment efficiency of a different formulation of 
NARNS. The concentration of the stabilizer used is the most effective 
factor on entrapment efficiency, and this agrees with that obtained 
by Patil et al. who formulate spray dried chitosan nanoparticles 
containing doxorubicin [44].  
 is due to C=0 stretching respectively. 
These distinctive bands of free NAR are also present in NARNS, 
which indicates the chemical stability of NAR in nanosuspensions 
[42, 43]. 
Drug entrapment efficiency 
Saturation solubility of freeze-drying nanosuspension 
The poor solubility of NAR that determined is in agreement with 
published researches as shown in table 3, also the results showed 
that an increase in pH resulted in an increase in the solubility of NAR 
as showing in the fig. this is because it is an acidic drug (pKa = 7.91). 
It was observed that the solubility of prepared NARNS has been 
increased to 6.1±0.2 folds in pH 1.2 and to 7.5±0.4 folds in pH 7.4 
due to the formation of stabilized nanosuspensions and it is shown 
in fig. 9 
 
 
Fig. 9: Saturation solubility studies of NAR and NARNS 
 
In vitro drug release 
In vitro, drug release profiles of NAR and NARNS are shown in fig. 10. A 
and 10. B. The release of NAR and the NARNS of the selected formulation 
were higher than the release profile of the pure drug in 60 min. The % 
CDR of the selected formula N2 was more than 90% in twelve h in both 
0.1 N HCl and phosphate buffer pH 7.4 media as compared to less than 
37.95 % and 24.82 % of NAR in the same media respectively. This will 
indicate that the dissolution rate of the NARNS is enhanced. Factors that 
contributing to a fast release was large surface area due to small particle 
size, high diffusion coefficient (small molecular size), low matrix 
viscosity and short diffusion distance of the drug [45]. 
 
 
Fig. 10A: Effect of NAR concentration and its NARNS in 0.1N Hcl pH 1.2, mean of three observation±SD (n=3) 
Sumathi et al. 




Fig. 10B: Effect of NAR concentration and its NARNS in Phosphate buffer pH 7.4, mean of three observation±SD (n=3) 
 
In vitro permeability studies 
The in vitro permeability study was carried out using Franz 
Diffusion Cell. After 1 h of diffusion, 97.13 % (N2), of the drug was 
diffused from the lyophilize nanosuspension, while for NAR, the 
diffusion was found to be 26.27 % respectively. Thus, the amount of 
the drug diffused through the nitrocellulose membrane has doubled 
when it is given to the form of a nanosuspension. It can be clearly 
seen that the permeation of the drug from lyophilized NARNS is 
much faster than the NAR. The enhanced diffusion may be explained 
in terms of the huge specific surface area of the nanosuspension 
droplets and improved permeation of the naringenin because of the 
presence of a surfactant, which reduces the interfacial tension of 
formulation [46]. The results are shown in fig. 11. 
 
 
Fig. 11: Comparative permeability studies of NAR and NARNS in phosphate buffer (pH 7.4), mean of three observation±SD. (n=3) 
 
Scanning electron microscope 
SEM was carried out to study the surface morphology of particles. It 
was found that NARNS revealed a smooth texture (fig. 12). The SEM 
picture of NAR particles was found abundantly with larger particle 
size when compared to NARNS. Thus, soya lecithin, polaxamer-407, 
poloaxamer 188, HPMC and Tween-80 produced better surface 
characteristics. The surface structure of nanosuspension in the SEM 
of N2 appeared good in shape. This micrograph was in agreement 
with those measured by particle size distribution [47]. 
 
 
Fig. 12(a): SEM of NAR, 13(b): SEM of Nar-Soya lecithin, 13(c): SEM of Nar-HPMC 13(d): SEM of Nar-polaxamer 188 13(e): SEM of Nar-
polaxamer 407 13(f): SEM of Nar-Tween-80 
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Powder X-ray diffraction analysis (P-XRD) 
A powder X-ray diffraction method is useful tools in identifying 
the physical nature of the particles. Powder x-ray diffraction 
patterns of free NAR, polymers and NARNS are present in fig. 
(13). Free NAR has displayed the characteristic crystalline peaks 
of 2θ of 10.83 ᵒ, 11.49 ᵒ, 15.75 ᵒ, 17.27 ᵒ, 18.07 ᵒ, 20.35 ᵒ, 23.73 ᵒ, 
25.37 ᵒ, 27.71 ᵒ. However, NARNS has not shown any such 
crystalline peaks. This absence of detectable crystalline domains 
of NAR in nanosuspension clearly indicates that NARNS is in 
amorphous or disordered crystalline phase or in the solid 
solution state [48]. 
 
 
Fig. 13(a): P-XRD of NAR, (b): P-XRD of Soya lecithin, (c): P-XRD of polaxamer-407, (d): P-XRD of Polaxamer-188, (e): P-XRD of HPMC, (f): 
P-XRD of Nar-Soya lecithin, (g): P-XRD of NAR-Polaxamer-407, (h): P-XRD of NAR-Polaxamer-188, (i): P-XRD of NAR-HPMC 
 
 
Fig. 14: a: DSC of NAR, (b): DSC of soya lecithin, (c): DSC of polaxamer-407, (d): DSC of polaxamer-188, (e): DSC of HPMC, (f): DSC of Nar-
Soya lecithin, (g): DSC of NAR-polaxamer-407, (h): DSC of NAR-polaxamer-188, (i): DSC of NAR-HPMC 
Sumathi et al. 




DSC was used to elucidate the physical state of the drug within the 
system. To investigate the molecular state of the drug, DSC study 
was carried out. The DSC curves of NAR and lyophilized NARNS 
were recorded. Fig. 14 Shows DSC thermo grams of free NAR, 
stabilizers and NARNS. Free NAR exhibited a melting endothermic 
peak around at 250 ◦
Stability studies 
C indicating the crystalline nature of the drug. 
However, NARNS showed broad melting peak indicating the absence 
of crystalline. Nature of the thermo gram is totally changed, and the 
sharp peaks are shifted; the peaks of NAR have changed to broad 
peaks with reduction of the height of each peak. These changes 
indicate that the dehydration of NAR and change as the particle size 
giving a more amorphous type as the product this may help in 
increasing the dissolution rate of NARNS. Lyophilized NARNS were 
molecularly dispersed in an amorphous form [49, 50]. 
The promising formulation (N2) was subjected to short-term 
accelerated stability study by storing the formulations at high-density 
polyethylene bottles and stored at 4±1 °C/Ambient, 25±2 °C/60±5 % 
RH %, 40±2°C/75±5 % RH for 90 d. After 3 mo, the formulation was 
again analyzed for drug content. The data for stability studies revealed 
that there was no considerable difference s in drug content. The 




Table 5: Stability studies of selected NARNS 
Storage temperature condition Initial drug content (%) Drug content after 90 d (%) 
N2 4 °C 99.52±0.13 99.13±0.41 
Room temperature 99.01±0.91 
40 °C 98.82±0.11 
 Mean of three observation±SD. (n=3) 
 
Hemocompatibility assay 
Erythrocyte hemolysis test for the formulated drug was conducted. 
If the hemolysis occurs, the oxyhemoglobin can drain out, and the 
amount of oxyhemoglobin is linear to the number of blood cells 
hemolyze. In the study, the rate of erythrocyte hemolysis of distilled 
water was set as 100% and physiological saline as 0%. The rate of 
erythrocyte hemolysis of formulated drug (NF2) dramatically 
decreased under the current experimental conditions. In general, the 
hemolysis % was not allowed to be higher than 5% for injection.  
The rates of erythrocytes hemolysis for 500–3.90 µg/ml were less of 
the formulated drug. It demonstrated that the nanosuspension 
formulation could reduce the damage to erythrocyte membrane 
effectively, which made this preparation amenable to i. v. injection 
and circumvented the problem of poor solubility. 
  
Table 6: Whole blood cell lysis 
S. No. Concentration (µg/ml) % hemolysis 
1 500 3.4±2.6 * 


















3.90 0.4±0.8 * 




NAR nanosuspension was successfully prepared by high-pressure 
homogenization technique. This method of manufacturing was 
found to be simple and has scale-up feasibility. The nanosuspension 
was converted into dry powder by lyophilization in order to increase 
its stability. The increase in drug dissolution rate and solubility can 
be expected to have a significant impact on the oral bioavailability of 
the drug. The in vitro 
CONFLICT OF INTERESTS 
intestinal permeability results showed that the 
drug diffusion across the intestinal membrane from the NARNS is 
significantly higher than the NAR suspension. DSC thermogram and 
P-XRD diffractograms confirmed that the crystalline was converted 
into amorphous nature after high-pressure homogenization and 
lyophilization process. Using SEM, it was found that NARNS revealed 
a smooth texture. The lyophilized NARNS was found to be stable 
when stored under refrigerated conditions. The hemocompatibility 
assessment results suggesting the formulated nanosuspension might 
be a good choice for intravenous administration of poorly soluble 
NAR. These observations lead us to the conclusion that 
nanosuspensions seem to be a promising drug delivery system, 
which can provide an effective and practical solution to the problem 
of NAR with low aqueous solubility and poor systemic 
bioavailability. Hence, these results suggest that the NARNS are 
highly promising cancer drug carrier system with interesting 
anticancer properties of NAR. 
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